Key result
Thienopyridine derivatives produced a modest reduction in serious vascular events compared with aspirin (11.6% vs 12.5%; OR 0.92, 95% CI 0.85-0.99).
Why the study?
Do thienopyridine derivatives reduce serious vascular events compared to aspirin in high vascular risk patients?
Systematic Review (n=26,865)
Double-blind
Do thienopyridine derivatives reduce serious vascular events compared to aspirin in high vascular risk patients?
Odds Ratio: 0.92 (95% CI 0.85–0.99)
Absolute Event Rate: 11.6% vs 12.5%
Thienopyridine derivatives (particularly clopidogrel) are at least as effective as aspirin for preventing serious vascular events in high-risk patients, serving as a viable alternative for those intolerant to aspirin.
No takes yet. Share an insight, caveat, or question.
Thienopyridines modestly outperform aspirin for vascular prevention; reinforces their role as first alternatives in high-risk patients.
Sudlow et al. (2009) conducted a systematic review in High vascular risk (n=26,865). Thienopyridine derivatives (ticlopidine and clopidogrel) vs. Aspirin was evaluated on serious vascular events (stroke, myocardial infarction (MI) or vascular death) (OR 0.92, 95% CI 0.85 to 0.99). Thienopyridine derivatives produced a modest reduction in serious vascular events compared with aspirin (11.6% vs 12.5%; OR 0.92, 95% CI 0.85-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: